tyrphostin a-1

Tyrphostin A1 (Tyrphostin 1) is an inhibitor of EGFR tyrosine kinase .

I-OMe-Tyrphostin AG 538 is a specific IGF-1R inhibitor and ATP-competitive inhibitor of PI5P4Kα (IC50: 1 µM).I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and exhibits preferential cytotoxicity to nutrient-deficient PANC1 cells.

Tyrphostin AG 538 is a chalcone compound, an IGF-1 receptor kinase inhibitor (IC₅0 : for 400 nM) that is potent, cell-permeable, reversible, and competitive.

Tyrphostin AG1433 (AG1433) is an inhibitor of tyrosine kinases and also a dual inhibitor of PDGFRβ(IC50s = 5.0 μM) and VEGFR-2 (Flk-1 KDR)(IC50s = 9.3 μM).

Tyrphostin 23 (AG18) inhibits EGFR with IC50 of 35 μM.

(Z)-Tyrphostin A51, the Z configuration of Lanoconazole A51, is a potent protein tyrosine kinase (PTK) inhibitor that dose-dependently inhibits the volume-sensitive release of [3 H]taurine in primary astrocyte cultures. It significantly reduces cellular tyrosyl phosphorylation levels and inhibits both basal and EGF-induced human bone cell proliferation [1] [2].

Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors[1].

Su1498 (Tyrphostin SU 1498) is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 (VEGFR2, aka FLK1; IC50 = 700 nM), having negligible activity at several other serine threonine and tyrosine kinases.1, 2 It effectively blocks signaling through VEGFR2 both in vitro and in vivo.1, 3 SU 1498 is used to study the role of VEGFR2 signaling in diverse processes, including angiogenesis, tumor growth, neural progenitor cell survival, and neuroregeneration.